Karius, Inc.
Karius, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Karius, Inc..
Karius, Inc. is a company.
Key people at Karius, Inc..
Key people at Karius, Inc..
Karius, Inc. is a clinical metagenomics company that develops advanced diagnostic tests for infectious diseases, using genomics and AI to detect over 1,000 pathogens from a single blood sample.[1][2][3] The company serves clinicians, hospitals, and transplant centers by offering the Karius Test, a liquid biopsy that identifies microbial cell-free DNA (mcfDNA) in bloodstream and deep-seated infections, enabling rapid treatment decisions and reducing reliance on invasive procedures.[1][2][3][5] This addresses critical delays in diagnosing vulnerable hospitalized patients, with solutions like the recent Karius Focus | BAL test for lung infections in immunocompromised individuals, showing strong growth through adoption by leading U.S. healthcare providers.[2][5]
Headquartered in Redwood City, California, with about 185 employees, Karius operates a CLIA-certified, CAP-accredited lab and emphasizes a mission to make infectious diseases no longer a major threat to human health.[2][3]
Karius was founded in 2014, built on intellectual property developed at Stanford University, marking a pivotal moment in translating academic metagenomics research into clinical tools.[2] The idea emerged from the need to overcome limitations in traditional diagnostics, leveraging next-generation sequencing (NGS) and proprietary bioinformatics to detect pathogens non-invasively.[1][2][4] Early traction came from its core product, the Karius Test, which quickly gained use in leading hospitals and transplant centers, evolving from a venture-backed startup focused on bloodstream infections to broader applications like pulmonary diagnostics.[2][3][5]
Leadership includes CEO Alec Ford, CSO Tim Blauwkamp, PhD, and other experts driving innovation from Stanford roots.[2]
Karius rides the metagenomics and AI diagnostics wave, transforming infectious disease management amid rising antimicrobial resistance and complex infections in aging, immunocompromised populations.[2][3][5] Timing is ideal post-pandemic, with market forces favoring precision medicine: demand for faster, non-invasive tests aligns with genomics cost reductions and AI scalability.[1][4][5] By influencing standards at major hospitals, Karius accelerates clinical trials, microbe discovery, and reduced patient suffering, contributing to a broader ecosystem shift toward data-driven pathogen detection.[3][5]
Karius is poised for expansion with new tests like Focus | BAL and potential international scaling, fueled by its Stanford heritage and venture backing (over raised funding noted in events).[2][5][8] Trends in AI-refined databases and multi-omics will sharpen its edge, potentially dominating hard-to-culture infections as hospitals prioritize rapid diagnostics. Its influence may grow through partnerships and trial acceleration, solidifying its role in a world free from infectious disease threats—echoing its founding vision of diagnostic breakthroughs.[1][2]